Revisiting dose-finding of monoclonal antibodies in migraine

Migraine is a debilitating disorder, and while the introduction of monoclonal antibodies (mAbs) has led to efficacious and tolerable responses, a substantial number of patients are so-called “non-responders”. We introduce reasons for this insufficient response, including insufficient blockade of Cal...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Hassany, Linda, Karsan, Nazia, Lampl, Christian, Goadsby, Peter J., MaassenVanDenBrink, Antoinette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251584/
https://www.ncbi.nlm.nih.gov/pubmed/37296378
http://dx.doi.org/10.1186/s10194-023-01602-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251584/
https://www.ncbi.nlm.nih.gov/pubmed/37296378
http://dx.doi.org/10.1186/s10194-023-01602-4

Ejemplares similares